Clinical Trial Results:
A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris Subjects with Active Disease
Summary
|
|
EudraCT number |
2006-003366-33 |
Trial protocol |
IT ES |
Global completion date |
31 Mar 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
14 Nov 2020
|
First version publication date |
24 Jun 2016
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
20201021_2006-003366-33_CT.gov_R_Posting (Updated) |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.